Parkinson's Disease With Motor Fluctuations
Conditions
Keywords
Parkinson's Disease, Motor Fluctuations, D1 partial agonist
Brief summary
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Detailed description
This is an open label study evaluating the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations. Subjects who completed Ph2 study B7601003 will be randomized to one of 4 treatment groups (15 mg QD, 7 mg QD, 3 mg QD, or 1 mg QD group) depending on the treatment received in B7601003 and titrated up to 15 mg QD over a 3 week period, as appropriate. All subjects who were blindly down-titrated during the B7601003 study will remain at/or be titrated to 7 mg QD only and remain at that dose for the rest of the B7601017 study in order to protect the blind for the prior study. Subjects who successfully titrate to 15 mg QD will enter the Adjustment Period at that dose. Subjects who cannot tolerate 15 mg QD at any time during the study will be allowed to down-titrate to 7 mg QD (but not lower) and will stay at that dose for the rest of the study. Subjects who cannot remain at a stable dose (7 mg or 15 mg QD) will be discontinued.
Interventions
DRUG1 mg QD to 15 mg QD PF-06649751
Up titration from 1 mg QD to 15 mg QD PF-06649751
DRUG3 mg QD to 15 mg QD PF-06649751
Up titration from 3 mg QD to 15 mg QD PF-06649751
DRUG7 mg QD to 15 mg QD PF-06649751
Up titration from 7 mg QD to 15 mg QD PF-06649751
DRUG15 mg QD PF-06649751
15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
DRUG1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
DRUG3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)
Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
DRUG7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)
7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
DRUG15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
During the titration phase, the allocation to treatment will be double blind to protect the blind of the parent study (B7601003). After completing the titration phase, the treatment assignment becomes open label.
Intervention model description
Depending on the actual treatment the subject received in B7601003, subjects will be randomized to one of 4 treatment groups (15 mg QD, 7 mg QD, 3 mg QD, or 1 mg QD group) and titrated up to 15 mg QD over a 3 week period, as appropriate. All subjects who were blindly down-titrated during the parent study (B7601003) will remain at/or be titrated to 7 mg QD only and remain at that dose for the rest of the B7601017 study in order to protect the blind for the parent study. Subjects who successfully titrate to 15 mg QD will enter the Adjustment Period at that dose. Subjects who cannot tolerate 15 mg QD at any time during the study will be allowed to down-titrate to 7 mg QD (but not lower) and will stay at that dose for the rest of the study. Subjects who cannot remain at a stable dose (7 mg or 15 mg QD) will be discontinued.
Eligibility
Sex/Gender
ALL
Age
40 Years to 87 Years
Healthy volunteers
No
Inclusion criteria
* Having successfully completed parent study B7601003. * Clinical diagnosis of Parkinson's disease. * Able to refrain from any Parkinson's disease medication not permitted by the protocol.
Exclusion criteria
* Female of childbearing potential. * Severe acute or chronic medical or psychiatric condition or laboratory abnormality. * Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | At last visit | The PWC-20 is a physician-completed, 20-item reliable and sensitive instrument for the assessment of benzodiazepine discontinuation symptoms, including anxiety and nervous, depersonalization and derealization, diarrhea, diaphoresis, difficulty concentrating and remembering, dizziness-lightheadedness, depression, fatigue, lethargy and lack of energy, headaches, increased acuity for sound, smell, touch, or pain, insomnia, irritability, loss of appetite, muscle aches or stiffness, nausea-vomiting paresthesias, poor coordination, restlessness and agitation, tremor-tremulousness, and weakness. Summaries of the count of participants experiencing symptoms and severity listed in the PWC-20 were provided. |
| Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Baseline to last visit after termination (up to approximately 3 months) | Number of participants with vital signs findings meeting the following criteria is presented:(1) standing DBP increase from baseline\>= 20 mm Hg; (2) standing SBP increase from baseline\>= 30 mm Hg; (3) supine DBP increase from baseline \>=20 mm Hg; (4) supine SBP increase from baseline \>=30 mm Hg; (5)standing DBP decrease from baseline\>= 20 mm Hg; (6) standing SBP decrease from baseline\>= 30 mm Hg; (7) supine DBP decrease from baseline \>=20 mm Hg; (8) supine SBP decrease from baseline \>=30 mm Hg. |
| Number of Participants With Vital Signs Data of Orthostatic Hypotension Meeting Pre-defined Criteria | Baseline to last visit after termination (up to approximately 3 months) | Orthostatic hypotension was defined as a decrease of \>=20 mmHg for systolic blood pressure (SBP) or \>=10 mmHg for diastolic blood pressure (DBP) 2 minutes after standing from a supine position. |
| Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | Baseline to last visit after termination (up to approximately 3 months) | PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS duration (time from Q wave to the end of S wave, corresponding to ventricle depolarization), QT interval (time from the beginning of Q wave to the end of T wave) and QTcF interval ( QT interval corresponding to electrical systole corrected for heart rate using Fridericia's formula) are summarized. Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval \>=300 msec; (2) QRS duration \>=140 msec; (3) QT interval \>= 500; (4) QTcF interval: 450 to \<480 msec; (5) QTcF interval: 480 to \<500 msec; (6) QTcF interval \>=500 msec. |
| Number of Participants With Worsening Suicidality and New Onset Suicidality | Baseline to last visit after termination (up to approximately 3 months) | The Columbia Suicide Severity Rating Scale (C-SSRS) is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. At each suicidality assessment, participants felt to have significant suicidal ideation with actual plan and intent or suicidal behavior, must be evaluated by a clinician/mental health professional (MHP) skilled in the evaluation of suicidality in the participants by virtue of training or experience who determined if it is safe for the participants to participate/continue in the trial. The denominator used in the percentages was the number of participants assessed for suicidality or worsening, the denominator included the subset of participants who had any level of suicidality reported at baseline. For new onset, the denominator included the subset of participants with no suicidality reported at baseline. |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities) | Baseline to last visit after termination (up to approximately 3 months) | An adverse event (AE) is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). |
| Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) | Baseline to last visit after termination (up to approximately 3 months) | An adverse event (AE) is any untoward medical occurrence in a study participant administered a product or medical device. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). |
| Number of Participants With Clinically Significant Findings in Physical Examination | Baseline to last visit after termination (up to approximately 3 months) | A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal and musculoskeletal systems. The clinical significance was determined by the investigator. |
| Number of Participants With Clinically Significant Findings in Neurological Examination | Baseline to last visit after termination (up to approximately 3 months) | The full neurological examination included assessment of the visual fields and of the right and left optic fundus; cranial nerves; mental state; muscle strength and tone, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station. Higher cortical and motor function was considered part of the complete neurological exam. The brief neurological exam included observation for cerebellar (intention) tremor and for non cerebellar tremors (eg, resting or positional), finger to nose, heel to shin, Romberg, gait and tandem walking, positional and gaze evoked nystagmus. The clinical significance was determined by the investigator. |
| Number of Participants With Abnormalities in Laboratory Test (Without Regard to Baseline Abnormality) | Baseline to last visit after termination(up to approximately 3 months) | Laboratory tests included hematology(hemoglobin,hematocrit,red and white blood cell count,mean corpuscular volume,mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,platelet count,neutrophils,eosinophils,monocytes, basophils,lymphocytes), chemistry(blood urea nitrogen/urea and creatinine,fasting glucose, calcium,sodium,potassium, chloride,total carbon dioxide,aspartate and alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid,albumin,total protein),urinalysis(pH,qualitative glucose protein,blood,ketones,nitrites,leukocyte esterase,urobilinogen,urine bilirubin,microscopy,specific gravity,urine creatinine),other tests(urine drug screen,follicle stimulating hormone,anti neutrophil cytoplasmic antibody panel,qualitative antinuclear antibody,fibrinogen,C reactive protein,erythrocyte sedimentation rate,C3, C4, CH50/CH100,rheumatoid factor,immunoglobulin panel,if anti- neutrophil cytoplasmic antibody positive:proteinase 3 Ab,myeloperoxidase Ab tests). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline for Hauser Participant Diary Data in Daily ON Time With Troublesome Dyskinesia | Baseline, Day 21 and Day 35 | Available diaries are designed to record participant motor state for half hour intervals. These diaries are a way for participants to assess their own health status without clinician bias or interpretation. ON time is defined as the time when medication is providing benefit with regard to mobility, slowness, and stiffness. ON time can be classified as associated with or without troublesome dyskinesia that interfere with activities of daily living.It has been demonstrated that ON time with troublesome dyskinesia are generally considered by participants to be bad time with regard to motor function. |
| Change From Baseline for Hauser Participant Diary Data in Daily ON Time Without Troublesome Dyskinesia | Baseline, Day 21 and Day 35 | Available diaries are designed to record participant motor state for half hour intervals. These diaries are a way for participants to assess their own health status without clinician bias or interpretation. ON time is defined as the time when medication is providing benefit with regard to mobility, slowness, and stiffness. ON time can be classified as associated with or without troublesome dyskinesia that interfere with activities of daily living. ON time without dyskinesia and on time with non troublesome dyskinesia are generally considered to be good time. |
| Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Baseline to last visit after termination (up to approximately 3 months) | The total MDS-UPDRS score developed by the Movement Disorder Society is the most common method of evaluating the severity of Parkinson's Disease (PD). Part I assesses non motor experiences of daily living(range 0-52).Part II assesses motor experiences of daily living(0-52). Part III assesses the motor signs of PD.Part IV assesses motor complications, dyskinesias, and motor fluctuations(0-24).Total Score:The sum of Parts I, II, III, and IV.Each question is anchored with five responses:0=normal, 1=slight, 2=mild, 3= moderate, 4=severe.Higher part and total scores indicate more severe signs of PD.There are four subscales in Part III:the tremor subscale(range 0-36),the rigidity subscale(0-20),the bradykinesia subscale(0-36),the postural instability and gait disorder (PIGD) subscale(0-12). |
| Change From Baseline for Hauser Participant Diary Data in Daily OFF Time | Baseline, Day 21 and Day 35 | Available diaries are designed to record participant motor state for half hour intervals. These diaries are a way for participant to assess their own health status without clinician bias or interpretation. In participant diaries, OFF time is defined as a period when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness. During this period, Parkinson's Disease (PD) participants experience relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| PF-06649751 15 mg Participants who completed Week 15 in Study B7601003 (NCT02687542) were orally administered PF-06649751 once daily (QD) at the last dose level used in Study B7601003 (1 mg, 3 mg, 7 mg or 15 mg, and original placebo participants starting from 1 mg) titrated up to 15 mg during a 3-week titration period, followed by a 2-week dose adjustment period (15 mg or if intolerance, reduced to 7 mg) and then followed by open-label maintenance treatment of PF-06649751 15 mg QD for 44 weeks or until discontinuation. | 5 |
| Total | 5 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Study Terminated by Sponsor | 4 |
Baseline characteristics
| Characteristic | PF-06649751 15 mg |
|---|---|
| Age, Continuous | 63 Years STANDARD_DEVIATION 11.73 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants |
| Race/Ethnicity, Customized Black or African American | 0 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race/Ethnicity, Customized Other | 0 Participants |
| Race/Ethnicity, Customized Unknown | 0 Participants |
| Race/Ethnicity, Customized White | 5 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 5 |
| other Total, other adverse events | 3 / 5 |
| serious Total, serious adverse events | 1 / 5 |
Outcome results
Primary
Number of Participants With Abnormalities in Laboratory Test (Without Regard to Baseline Abnormality)
Laboratory tests included hematology(hemoglobin,hematocrit,red and white blood cell count,mean corpuscular volume,mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,platelet count,neutrophils,eosinophils,monocytes, basophils,lymphocytes), chemistry(blood urea nitrogen/urea and creatinine,fasting glucose, calcium,sodium,potassium, chloride,total carbon dioxide,aspartate and alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid,albumin,total protein),urinalysis(pH,qualitative glucose protein,blood,ketones,nitrites,leukocyte esterase,urobilinogen,urine bilirubin,microscopy,specific gravity,urine creatinine),other tests(urine drug screen,follicle stimulating hormone,anti neutrophil cytoplasmic antibody panel,qualitative antinuclear antibody,fibrinogen,C reactive protein,erythrocyte sedimentation rate,C3, C4, CH50/CH100,rheumatoid factor,immunoglobulin panel,if anti- neutrophil cytoplasmic antibody positive:proteinase 3 Ab,myeloperoxidase Ab tests).
Time frame: Baseline to last visit after termination(up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PF-06649751 15 mg | Number of Participants With Abnormalities in Laboratory Test (Without Regard to Baseline Abnormality) | 1 Participants |
Primary
Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20)
The PWC-20 is a physician-completed, 20-item reliable and sensitive instrument for the assessment of benzodiazepine discontinuation symptoms, including anxiety and nervous, depersonalization and derealization, diarrhea, diaphoresis, difficulty concentrating and remembering, dizziness-lightheadedness, depression, fatigue, lethargy and lack of energy, headaches, increased acuity for sound, smell, touch, or pain, insomnia, irritability, loss of appetite, muscle aches or stiffness, nausea-vomiting paresthesias, poor coordination, restlessness and agitation, tremor-tremulousness, and weakness. Summaries of the count of participants experiencing symptoms and severity listed in the PWC-20 were provided.
Time frame: At last visit
Population: The population for PWC-20 included participants who completed study treatment and who participated the first visit of follow-up
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Insomnia | Mild | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Tremor-Tremulousness | Mild | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Anxiety, Nervousness | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Anxiety, Nervousness | Mild | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Anxiety, Nervousness | Moderate | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Anxiety, Nervousness | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Difficult Concentrating, Remembering | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Difficult Concentrating, Remembering | Mild | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Difficult Concentrating, Remembering | Moderate | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Difficult Concentrating, Remembering | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Dysphoric Mood, Depression | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Dysphoric Mood, Depression | Mild | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Dysphoric Mood, Depression | Moderate | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Dysphoric Mood, Depression | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Fatigue, Lethargy, Lack of Energy | Not Present | 2 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Fatigue, Lethargy, Lack of Energy | Mild | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Fatigue, Lethargy, Lack of Energy | Moderate | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Fatigue, Lethargy, Lack of Energy | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Insomnia | Not Present | 2 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Insomnia | Moderate | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Insomnia | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Irritability | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Irritability | Mild | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Irritability | Moderate | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Irritability | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Muscle Aches or Stiffness | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Muscle Aches or Stiffness | Mild | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Muscle Aches or Stiffness | Moderate | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Muscle Aches or Stiffness | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Poor Coordination | Not Present | 2 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Poor Coordination | Mild | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Poor Coordination | Moderate | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Poor Coordination | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Restlessness, Agitation | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Restlessness, Agitation | Mild | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Restlessness, Agitation | Moderate | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Restlessness, Agitation | Severe | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Tremor-Tremulousness | Not Present | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Tremor-Tremulousness | Moderate | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Tremor-Tremulousness | Severe | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Weakness | Not Present | 2 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Weakness | Mild | 2 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Weakness | Moderate | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | Weakness | Severe | 0 Participants |
Primary
Number of Participants With Clinically Significant Findings in Neurological Examination
The full neurological examination included assessment of the visual fields and of the right and left optic fundus; cranial nerves; mental state; muscle strength and tone, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station. Higher cortical and motor function was considered part of the complete neurological exam. The brief neurological exam included observation for cerebellar (intention) tremor and for non cerebellar tremors (eg, resting or positional), finger to nose, heel to shin, Romberg, gait and tandem walking, positional and gaze evoked nystagmus. The clinical significance was determined by the investigator.
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period and had a post-baseline neurological examination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PF-06649751 15 mg | Number of Participants With Clinically Significant Findings in Neurological Examination | 0 Participants |
Primary
Number of Participants With Clinically Significant Findings in Physical Examination
A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal and musculoskeletal systems. The clinical significance was determined by the investigator.
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period and had a post-baseline physical examination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PF-06649751 15 mg | Number of Participants With Clinically Significant Findings in Physical Examination | 0 Participants |
Primary
Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria
PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization), QRS duration (time from Q wave to the end of S wave, corresponding to ventricle depolarization), QT interval (time from the beginning of Q wave to the end of T wave) and QTcF interval ( QT interval corresponding to electrical systole corrected for heart rate using Fridericia's formula) are summarized. Number of participants with ECG findings meeting the following criteria is presented: (1) PR interval \>=300 msec; (2) QRS duration \>=140 msec; (3) QT interval \>= 500; (4) QTcF interval: 450 to \<480 msec; (5) QTcF interval: 480 to \<500 msec; (6) QTcF interval \>=500 msec.
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| PF-06649751 15 mg | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | PR Interval (aggregate) >= 300 msec | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | QRS Duration (aggregate) >= 140 msec | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | QT Interval (aggregate) >= 500 msec | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | QTcF Interval (aggregate) >= 450 msec, <480msec | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | QTcF Interval (aggregate) >= 480 msec, <500msec | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | QTcF Interval (aggregate) >= 500 msec | 0 Participants |
Primary
Number of Participants With Treatment-Emergent Adverse Events (All Causalities)
An adverse event (AE) is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE).
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PF-06649751 15 mg | Number of Participants With Treatment-Emergent Adverse Events (All Causalities) | 3 Participants |
Primary
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related)
An adverse event (AE) is any untoward medical occurrence in a study participant administered a product or medical device. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE).
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| PF-06649751 15 mg | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) | 2 Participants |
Primary
Number of Participants With Vital Signs Data Meeting Pre-defined Criteria
Number of participants with vital signs findings meeting the following criteria is presented:(1) standing DBP increase from baseline\>= 20 mm Hg; (2) standing SBP increase from baseline\>= 30 mm Hg; (3) supine DBP increase from baseline \>=20 mm Hg; (4) supine SBP increase from baseline \>=30 mm Hg; (5)standing DBP decrease from baseline\>= 20 mm Hg; (6) standing SBP decrease from baseline\>= 30 mm Hg; (7) supine DBP decrease from baseline \>=20 mm Hg; (8) supine SBP decrease from baseline \>=30 mm Hg.
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Standing DBP increase from baseline >= 20 mm Hg | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Standing SBP increase from baseline >= 30 mm Hg | 1 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Supine DBP increase from baseline >= 20 mm Hg | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Supine SBP increase from baseline >= 30 mm Hg | 2 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Standing DBP decrease from baseline >= 20 mm Hg | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Standing SBP decrease from baseline >= 30 mm Hg | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Supine DBP decrease from baseline >= 20 mm Hg | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Supine SBP decrease from baseline >= 30 mm Hg | 0 Participants |
Primary
Number of Participants With Vital Signs Data of Orthostatic Hypotension Meeting Pre-defined Criteria
Orthostatic hypotension was defined as a decrease of \>=20 mmHg for systolic blood pressure (SBP) or \>=10 mmHg for diastolic blood pressure (DBP) 2 minutes after standing from a supine position.
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| PF-06649751 15 mg | Number of Participants With Vital Signs Data of Orthostatic Hypotension Meeting Pre-defined Criteria | DBP postural difference>=10 mm Hg(Supine-Standing) | 3 Participants |
| PF-06649751 15 mg | Number of Participants With Vital Signs Data of Orthostatic Hypotension Meeting Pre-defined Criteria | SBP postural difference>=20 mm Hg(Supine-Standing) | 4 Participants |
Primary
Number of Participants With Worsening Suicidality and New Onset Suicidality
The Columbia Suicide Severity Rating Scale (C-SSRS) is an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. At each suicidality assessment, participants felt to have significant suicidal ideation with actual plan and intent or suicidal behavior, must be evaluated by a clinician/mental health professional (MHP) skilled in the evaluation of suicidality in the participants by virtue of training or experience who determined if it is safe for the participants to participate/continue in the trial. The denominator used in the percentages was the number of participants assessed for suicidality or worsening, the denominator included the subset of participants who had any level of suicidality reported at baseline. For new onset, the denominator included the subset of participants with no suicidality reported at baseline.
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| PF-06649751 15 mg | Number of Participants With Worsening Suicidality and New Onset Suicidality | New Onset | 0 Participants |
| PF-06649751 15 mg | Number of Participants With Worsening Suicidality and New Onset Suicidality | Worsening | 0 Participants |
Secondary
Change From Baseline for Hauser Participant Diary Data in Daily OFF Time
Available diaries are designed to record participant motor state for half hour intervals. These diaries are a way for participant to assess their own health status without clinician bias or interpretation. In participant diaries, OFF time is defined as a period when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness. During this period, Parkinson's Disease (PD) participants experience relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia.
Time frame: Baseline, Day 21 and Day 35
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily OFF Time | Baseline | 3.25 Hours |
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily OFF Time | Day 21 | 0.00 Hours |
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily OFF Time | Day 35 | -0.42 Hours |
Secondary
Change From Baseline for Hauser Participant Diary Data in Daily ON Time Without Troublesome Dyskinesia
Available diaries are designed to record participant motor state for half hour intervals. These diaries are a way for participants to assess their own health status without clinician bias or interpretation. ON time is defined as the time when medication is providing benefit with regard to mobility, slowness, and stiffness. ON time can be classified as associated with or without troublesome dyskinesia that interfere with activities of daily living. ON time without dyskinesia and on time with non troublesome dyskinesia are generally considered to be good time.
Time frame: Baseline, Day 21 and Day 35
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily ON Time Without Troublesome Dyskinesia | Baseline | 9.58 Hours |
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily ON Time Without Troublesome Dyskinesia | Day 21 | 1.17 Hours |
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily ON Time Without Troublesome Dyskinesia | Day 35 | 2.42 Hours |
Secondary
Change From Baseline for Hauser Participant Diary Data in Daily ON Time With Troublesome Dyskinesia
Available diaries are designed to record participant motor state for half hour intervals. These diaries are a way for participants to assess their own health status without clinician bias or interpretation. ON time is defined as the time when medication is providing benefit with regard to mobility, slowness, and stiffness. ON time can be classified as associated with or without troublesome dyskinesia that interfere with activities of daily living.It has been demonstrated that ON time with troublesome dyskinesia are generally considered by participants to be bad time with regard to motor function.
Time frame: Baseline, Day 21 and Day 35
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily ON Time With Troublesome Dyskinesia | Baseline | 0.00 Hours |
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily ON Time With Troublesome Dyskinesia | Day 21 | 0.00 Hours |
| PF-06649751 15 mg | Change From Baseline for Hauser Participant Diary Data in Daily ON Time With Troublesome Dyskinesia | Day 35 | 0.00 Hours |
Secondary
Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score
The total MDS-UPDRS score developed by the Movement Disorder Society is the most common method of evaluating the severity of Parkinson's Disease (PD). Part I assesses non motor experiences of daily living(range 0-52).Part II assesses motor experiences of daily living(0-52). Part III assesses the motor signs of PD.Part IV assesses motor complications, dyskinesias, and motor fluctuations(0-24).Total Score:The sum of Parts I, II, III, and IV.Each question is anchored with five responses:0=normal, 1=slight, 2=mild, 3= moderate, 4=severe.Higher part and total scores indicate more severe signs of PD.There are four subscales in Part III:the tremor subscale(range 0-36),the rigidity subscale(0-20),the bradykinesia subscale(0-36),the postural instability and gait disorder (PIGD) subscale(0-12).
Time frame: Baseline to last visit after termination (up to approximately 3 months)
Population: The study population included all participants who received at least 1 dose of study medication during the study period.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| PF-06649751 15 mg | Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Part I Score | -1.5 Units on a scale |
| PF-06649751 15 mg | Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Part II Score | 0 Units on a scale |
| PF-06649751 15 mg | Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Part III Score | -2.5 Units on a scale |
| PF-06649751 15 mg | Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Part IV Score | 0 Units on a scale |
| PF-06649751 15 mg | Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Total Score | 0 Units on a scale |